RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Life Extension Ventures
L

Life Extension Ventures portfolio

Life Extension Ventures has 5 portfolio companies on record at Recent Funding.

Type: Investor.
Portfolio on Recent Funding: 5.
Deals, last 12 months: 0.
Capital in their rounds: $14.66M.
Latest deal: Imu Biosciences · Jan 24, 2024.
About this page

Its most recent investment on record is Imu Biosciences's $14.66M Series A round in January 2024, alongside Molten Ventures and COREangels. By category, its portfolio leans toward Health and bio (2) and AI agents (2).

Funds raised

FundFund #SizeAnnounced
LLife Extension Ventures
NYC, London, SF
Ifirst fund$100M
techcrunch.com

What Life Extension Ventures invests in

How Life Extension Ventures invests

StageDealsCapital in rounds
Series A 1 100%$14.66M

Life Extension Ventures portfolio companies

CompanyRound with Life Extension VenturesTotal raisedLatest raise
IImu Biosciences
Health and bio
Series A · $14.66M$67.66MJun 1, 2026
Series A
KKonko AI
AI agents
backer$6MSep 2, 2026
Seed
CCortical Labs backer$10MOct 10, 2024
Seed
FFraction AI
AI agents
backer$6MDec 19, 2024
Pre-seed
PPaack
Commerce and retail
backer$225MJan 26, 2022
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Venture funds Life Extension Ventures raised, from the list of new VC funds compiled by Shai Goldman (Brex). Each size links to the article that states it, or to that list where no article was found. All new funds: new VC funds.

Share is of the 1 round on Recent Funding that name Life Extension Ventures. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Life Extension Ventures, which is a subset of its real portfolio. API: /api/v1/investors/life-extension-ventures (get a free API key). More: the most active VC firms and new venture capital funds.